Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-01-19-Speech-3-385-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110119.20.3-385-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Asthma attacks cause sudden breathing difficulties that can even last for hours.
Germany introduced a ban on the sale of particular asthma inhalers first in 1997 and then again in 2005. The Commission was called on to respond regarding the legitimacy of the bans but never issued a ruling, thus breaching the safeguard clause procedure laid down by Directive 93/42/EEC, which should have obliged the Commission to do so.
The seriousness of this omission is made all the more acute by the fact that, according to reliable estimates, the inhalers withdrawn from the market could have improved the quality of life of some 30 million asthma sufferers.
The question tabled by Mrs Mazzoni calls on the Commission to respond regarding the failure to comply with the safeguard clause prescribed in Article 8 of Directive 93/42/EEC. According to this article, when the Commission is called on to rule on a national legislative measure in the field of health, it must enter into consultation with the parties concerned as soon as possible and inform them of the legitimacy or otherwise of the national measure. At this point in the procedure, as the Court of Justice has also ruled, a committee of inquiry needs to be set up to ascertain the Commission’s actual liability."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples